The HCPLive conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.
Guselkumab Leads to Rapid Ulcerative Colitis Symptom Improvement
Induction treatment with guselkumab resulted in a rapid onset of efficacy, beginning at week 1 and increasing over time to week 12, for patients with refractory moderately to severely active ulcerative colitis.
MACE, VTE Risk Not Increased by Advanced Therapies for Inflammatory Bowel Disease
Advanced therapies for inflammatory bowel disease, namely small molecules and biologic therapies, did not increase the risk of a major adverse cardiovascular event or venous thromboembolism.
Diet and Food Access Are Risk Factors for Early Onset Colorectal Cancer Mortality
Consumption of fruit and vegetables was found to be protective while consuming sweet snacks and candy along with supercenters and warehouse clubs as a primary food source were determined to be risk factors for early onset colorectal cancer mortality.
Alcohol Use Disorder Diagnosis, Treatment Associated with Decreased Risk of Mortality
October 23rd 2023Presented at ACG 2023, findings from a retrospective cohort analysis revealed patients with ALD diagnosed with and prescribed at least 1 medication for alcohol use disorder had a decreased risk of mortality.
Tapinarof Cream 1% Rapidly Improves Mild to Severe Plaque Psoriasis
Patients with plaque psoriasis, including in intertriginous areas and genitalia, experienced rapid improvement when treated with tapinarof cream 1%, offering an effective and well-tolerated nonsteroidal option for this condition.
Next-Generation Cologuard Improves Colorectal Cancer Detection, False Positive Rates in BLUE-C
October 23rd 2023Thomas F. Imperiale, MD, discusses the pivotal findings showing improvements to the prior iteration of Cologuard, as well as bettered sensitivity and specificty relative to fecal immunochemical tests.
Tildrakizumab Significantly Improves Work Productivity in Moderate to Severe Plaque Psoriasis
Tildrakizumab significantly improved work productivity and reduced work activity impairment in patients with moderate to severe plaque psoriasis, highlighting this treatment's quality of life benefits.